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A B S T R A C TObjectives: To characterize work productivity in relapsing multiple
sclerosis (MS) by using a work productivity scale and to identify
associations between work productivity and disability, depression,
fatigue, anxiety, cognition, and health-related quality of life. Methods:
Three hundred seventy-seven subjects with a clinically isolated
syndrome or relapsing remitting MS participated in the study. Sub-
jects underwent neurological examinations and completed patient-
reported outcome and cognitive measures. Subjects also completed
the Work Productivity and Activity Impairment Questionnaire: Gen-
eral Health to quantify absenteeism (missing work because of health
problems), presenteeism (impairment while working), overall work
impairment, and daily activity impairment attributable to health
problems. Univariate correlations and multivariate models were used
to determine the associations between each work productivity vari-
able and clinical, patient-reported outcome, and cognitive measures.
Results: Seventy-six percent of subjects were employed. Fourteen
percent of working subjects reported absenteeism, and 47% reported
presenteeism. The mean work time lost because of absenteeism wasnt matter Copyright & 2012, International Society
r Inc.
.1016/j.jval.2012.07.010
artners.org.
ondence to: Bonnie I. Glanz, Partners Multiple Scler4%, and the mean work time lost because of presenteeism was 12%.
Absenteeism was not significantly associated with disease or patient-
reported outcome measures. Statistically significant correlations
(0.32–0.53) were found between presenteeism and increasing dis-
ability, fatigue, depression, anxiety, and reduced quality of life. No
associations were observed between presenteeism and disease dura-
tion or cognitive function. Conclusions: Subjects with clinically iso-
lated syndrome/relapsing remitting MS reported substantial work
productivity losses due to presenteesim. Presenteeism was associated
with increasing fatigue, depression, anxiety, and reduced quality of
life. It is possible that the early identification and treatment of fatigue
and mental health symptoms may improve productivity while work-
ing and extend employment for individuals with MS.
Keywords: depression, fatigue, multiple sclerosis, quality of life, work
productivity.
Copyright & 2012, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Multiple sclerosis (MS) is a chronic demyelinating disease that
affects the central nervous system. Approximately 400,000 indi-
viduals in the United States report having MS [1]. Common
symptoms include numbness, problems with walking, balance,
and coordination, bladder and bowel complaints, visual impair-
ment, fatigue, depression, and cognitive dysfunction [2]. Most
individuals have a first episode of demyelination or a clinically
isolated syndrome (CIS) followed by a relapsing remitting disease
course that is characterized by clearly defined attacks of worsen-
ing neurologic function with full or partial recovery. The majority
of patients with relapsing remitting MS (RRMS) transition to a
progressive phase known as secondary progressive MS. Fewer
individuals present with primary progressive MS or progressive
relapsing MS, which both have a slowly progressive course from
onset [3]. MS is usually diagnosed between the ages of 20 and 50years, significantly affecting education, career, and family life [4].
It also impacts employment. Unemployment rates among indi-
viduals with MS have been shown to be as high as 80% [5].
Numerous studies have examined factors related to employ-
ment status in MS. Increasing age [6,7], greater physical disability
[4,6,8], a progressive disease course [9–11], and higher levels
of fatigue [7,9] and anxiety [4] have all been associated with
unemployment. Depression has been strongly related to unemploy-
ment in some [12] but not all studies in MS [6,9]. Similarly, gender
[7,12], disease duration [4,12], and cognitive dysfunction [6,9,13]
have been inconsistently associated with employment status.
Among working individuals with MS, research has tradition-
ally focused on absenteeism or number of workdays missed.
Individuals with MS have been shown to have significantly higher
rates of medically related absenteeism and associated absentee-
ism days than employee controls. In a study by Ivanova et al. [14],
employees with MS had four times more workdays lost than didfor Pharmacoeconomics and Outcomes Research (ISPOR).
osis Center, 1 Brookline Place, Suite 227, Brookline, MA 02445.
1567 CLIMB subjects with
clinical visit between July
2010 and November 2011
480 subjects completed
PRO measures during this
interval
460 subjects with WPAI
information
1087 subjects did not
complete PRO measures
during this interval
20 subjects missed either the
work status question or all
the remaining WPAI questions
78 subjects had a disease
category other than
RRMS/CIS
382 RRMS/CIS subjects
had WPAI information
5 subjects had errors in
data entry
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MS has been associated with the overall severity of illness [15].
Higher rates of comorbid diagnoses such as mental health
disorders and other neurological disorders have been reported
in MS [14] and may also impact time missed from work.
There is increasing evidence that presenteeism—reduced pro-
ductivity while working—may be important in evaluating work
productivity losses in individuals with chronic diseases. In arthri-
tis, for example, it has been estimated that presenteeism accounts
for 41% of total productivity losses while absenteeism accounts for
only 10% [16]. In addition, presenteeism may correlate with health
status better than absenteeism. Zhang et al. [17] reported stronger
correlations between presenteeism and health status measures
including functional disability, pain, fatigue, and disease activity
than between absenteeism and the same health status measures
in a group of subjects with rheumatoid arthritis.
In this report, our first goal was to characterize work produc-
tivity including absenteeism and presenteeism in individuals with
a CIS or RRMS by using a work productivity scale. Given that the
ability to work has been shown to vary across disease types, this
study was limited to subjects with relapsing disease. Our second
goal was to examine the associations between work productivity
measures and demographic and disease characteristics, patient-
reported outcomes (PROs) such as depression, fatigue, anxiety, and
health-related quality of life, and cognitive function.377 RRMS/CIS subjects
contributed to the final
analysis
Fig. 1 – Flow diagram summarizing how the overall study
population was reduced to the final cohort.
Table 1 – Demographic characteristics of study subjects.
N 377
Age (y), mean 7 SD 45.47 10.6
Disease duration (y), mean 7 SD 12.47 7.8
% of males 23.9
Race (%)
Asian 0.8
Black or African American 2.1
More than one race 1.1
Unknown or not reported 1.1
White 95.0
Ethnicity (%)
Hispanic or Latino 4.0
Non-Hispanic or Latino 95.5
Unknown 0.5
Disease category (%)
RRMS 94.7
CIS 5.3
EDSS, median (IQR) 1.5 (0–2.5)
% treated 71.7
SDMT score, mean 7 SD 56.77 12.5
% working 75.6
CIS, clinically isolated syndrome; EDSS, Expanded Disability Status
Scale; IQR, interquartile range; RRMS, relapsing remitting multiple
sclerosis; SDMT, Symbol Digit Modalities Test.Methods
Subjects
Subjects with CIS/RRMS were selected from the Comprehensive
Longitudinal Investigation of Multiple Sclerosis at the Brigham and
Women’s Hospital, Partner’s MS Center (CLIMB) study, an ongoing
prospective observational cohort study that began enrolling sub-
jects in 2000 [18]. Inclusion criteria for the CLIMB study are age 18
years or older and CIS with a positive magnetic resonance imaging
(MRI) scan with two or more lesions characteristic of MS or a
diagnosis of MS according to the revised McDonald criteria [19].
Patients are approached about possible study participation by their
physicians during their routine visits to the Partner’s MS Center. To
date, 1879 subjects have been enrolled. This represents nearly half
of the patients with MS followed at our center.
CLIMB subjects have clinical visits every 6 months that include
complete neurological examinations. Current levels of disability
are determined by using the Expanded Disability Severity Scale
(EDSS) [20], an ordinal clinical rating scale with total scores
ranging from 0 (normal neurologic examination) to 10 (death due
to MS), in increments of 0.5. A subset of subjects also completes
PRO and cognitive measures annually. The original battery
included depression, fatigue, health-related quality of life, and
working memory tests using the measures described in detail
below. Beginning in July 2010, subjects began completing addi-
tional questionnaires to assess work productivity and anxiety. For
each subject, the last clinical visit with associated questionnaire
data was used. Because only a subset of the CIS/RRMS CLIMB
subjects has completed the new questionnaires, our final sample
size was 377 subjects. Fig. 1 summarizes how the overall study
population was reduced to the final cohort. Demographic and
clinical characteristics of subjects are provided in Table 1.
PRO and Cognitive Measures
PRO and cognitive measures include the Multiple Sclerosis
Quality of Life-54 [21], Center for Epidemiologic Studies Depres-
sion Scale [22], Modified Fatigue Impact Scale (MFIS) [23],
State-Trait Anxiety Inventory for Adults (STAI) [24], and SymbolDigit Modalities Test (SDMT) [25,26]. The Multiple Sclerosis
Quality of Life-54 is a 54-item questionnaire that includes the
Medical Outcomes Study Short-Form 36 Health Survey (SF-36) [27]
and 18 MS-specific items. The SF-36 items were combined by
Table 2 – WPAI and PRO scores.
Score Mean7 SD, n
Absenteeism (percent work time missed) 3.67 13.0, 274
Presenteeism (percent impairment while
working)
11.9 7 17.3, 271
Overall work impairment 14.5 7 21.1, 274
Activity impairment 17.7 7 24.4, 375
CES-D 28.87 7.8, 372
MFIS 23.3 7 16.7, 374
STAI-State 31.1 7 11.0, 373
STAI-Trait 33.8 7 11.1, 374
CES-D, Center for Epidemiologic Studies Depression Scale; MFIS,
Modified Fatigue Impact Scale; PRO, patient-reported outcome;
STAI, State-Trait Anxiety Inventory for Adults; WPAI, Work Pro-
ductivity and Activity Impairment Questionnaire.
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Life Inventory [28] to provide eight scale T scores with means of
50 and SDs of 10 (Physical Functioning, Role-Physical, Bodily Pain,
General Health, Vitality, Social Functioning, Role-Emotional, and
Mental Health) and two summary scores also with means of 50
and SDs of 10 (Physical Component Summary [PCS] and Mental
Component Summary). The Center for Epidemiologic Studies
Depression Scale is a 20-item measure of depression that focuses
on the cognitive and affective rather than the somatic compo-
nents of depression. The MFIS is a 21-item fatigue scale that
measures the physical, cognitive, and psychosocial aspects of
fatigue. The STAI assesses the current temporary condition of
‘‘state anxiety’’ and the more general and long-standing
quality of ‘‘trait anxiety.’’ For all these PRO measures, only
those subjects who answered all questions relevant for the total
score were included in the analysis. The SDMT is a measure
of speed of information processing and working memory. Subjects
are asked to orally substitute numbers for symbols as part of a set
code. Scores are the number of correct responses in 90 seconds.
Work productivity is assessed by using the Work Productivity
and Activity Impairment Questionnaire: General Health version
2.0 (WPAI:GH) [29]. The WPAI:GH was selected because it is self-
administered, consists of a small number of questions, and has a
recall period of 7 day to reduce recall bias. Because it does not ask
questions specific to the type of illness or the type of employ-
ment, it is generalizable across occupations and illnesses [30].
The WPAI:GH consists of six questions regarding the effect of
health problems on the ability to work and perform regular
activities during the past 7 day. The first question was altered
to obtain more information about the status of the subjects who
were not working for pay. Rather than asking subjects whether
they were currently employed (working for pay), we asked them
to choose among the following categories: 1) working for pay, 2)
working in the home by choice, 3) volunteering, 4) in school, 5)
temporarily not working but looking for work, 6) not working
because of age, and 7) not working because of disease. The
answers to the remaining five questions are combined to obtain
four WPAI:GH outcomes that are expressed as impairment
percentages, with higher numbers indicating greater impairment
and less productivity: percentage of work time missed due to
health problems (absenteeism), percentage of impairment while
working due to health problems (presenteeism), percentage of
overall work impairment due to health problems, and percentage
of activity impairment due to health problems. The first three of
these outcomes are calculated only for those subjects who are
working for pay, and the last outcome is calculated for all
subjects. The number of hours lost because of reduced produc-
tivity while at work was calculated as the number of hours
worked multiplied by the percent impairment while working due
to health problems [31].
Statistical Analysis
The means and SDs for each of the WPAI:GH outcomes were
calculated. The correlations between WPAI:GH scores and clin-
ical, PRO, and cognitive measures were assessed by using Pear-
son’s correlation coefficient, and the correlations between
WPAI:GH scores and EDSS were assessed by using Spearman’s
correlation coefficient. In addition to the univariate correlations,
multivariate models for each WPAI:GH impairment measure were
analyzed with EDSS, disease duration, depression, anxiety, fati-
gue, and cognitive function as predictors. Given the skewed
nature of the data, we used bootstrap standard errors to provide
the reported confidence intervals (CIs) for the correlation coeffi-
cients and linear regression coefficients [32]. This approach has
been suggested by several authors including Walters and Camp-
bell [33] and Delucchi and Bostrom [34]. In addition, following thesuggestion of Delucci and Bostrom [34], we included an analysis
comparing the presence versus absence of impairment for each
of the outcomes. Although the bootstrap results are presented,
similar results were observed by using model-based estimates.
EachWPAI:GH score was also dichotomized on the basis of the
presence/absence of any impairment, and the proportions of
subjects with impairment on each of the WPAI:GH outcomes
were calculated. The impact of each of the clinical, PRO, and
cognitive measures on the probability of impairment was
assessed by using logistic regression. For all analyses, 95% CIs
were used to assess statistical significance.Results
WPAI:GH Scores
Seventy-six percent of subjects with CIS/RRMS (285 of 377) were
working for pay at the time of the survey, 6.4% were working in
the home, 1.6% were volunteering, 4.0% were in school, 3.4% were
temporarily not working but looking for work, 2.1% were not
working or looking for work because of age, and 6.9% were not
working or looking for work because of disability. Among the
subjects who were working for pay, 11 patients reported that they
did not work during the previous week but that missed work was
not due to health problems (i.e., on vacation), and so they were
removed from the subsequent analysis. Of the remaining 274
patients, 13.9% (38 of 274) reported some missed work due to
health problems and three patients reported missing the entire
week of work because of health problems (100% absenteeism).
The mean percent work time lost because of absenteeism was
3.6%. For the patients who worked during the previous week,
46.5% (126 of 271) reported presenteeism and the mean percent
impairment while working was 11.9% (Table 2). The proportion of
subjects who reported any overall work impairment was 47.8%
(131 of 274), and the mean percent overall work impairment was
14.5%. The proportion of subjects who reported any activity
impairment was 53.1% (199 of 375), and the mean percent activity
impairment was 17.7% (Table 2, two patients failed to answer this
question).
Predictors of Work Productivity Measures
Among the subjects who were working, the correlations between
the clinical/PRO/cognitive measures and the work productivity
outcomes are presented in Table 3. Absenteeism was significantly
correlated with SF-36 PCS, SF-36 Role-Physical, and SDMT. In
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regression, statistically significant effects were observed for
several PRO measures (CES-D, MFIS, STAI-State, STAI-Trait, SF-
36 MCS, SF-36 PCS, and all SF-36 component scales) (see Table 1
in Supplemental Materials found at http://dx.doi.org/10.1016/j.
jval.2012.07.010). When the multivariate model for absenteeism
was investigated, no variables were significantly associated with
work time missed (Table 4). The R2 value for the full model was
0.015, demonstrating that the multivariate model explained a
limited amount of the variance in work time missed. These
results indicate that although some of the predictors are useful
in predicting the presence of absenteeism, they do not provide
significant information about the mean amount of absenteeism
given the small percentage of subjects who reported absenteeism
over the last week.
Statistically significant correlations were observed between
PROs and presenteeism (Table 3). These results show that
presenteeism was associated with increasing depression, fatigue,
anxiety, disability, and decreasing quality of life for each of the
SF-36 scales. The strongest correlations with presenteeism were
observed for fatigue (r ¼ 0.54; 95% CI 0.35–0.63), Role-Physical
(r ¼  0.57; 95% CI  0.66 to  0.42), and Social Functioning
(r ¼  0.53; 95% CI  0.63 to  0.38). No statistically significant
correlations between presenteeism and cognitive functioning or
disease duration were observed. In logistic regression models (see
Table 1 in Supplemental Materials found at http://dx.doi.org/10.
1016/j.jval.2012.07.010 ), the strongest associations were seen
with the same factors that were most associated with the
presenteeism score, and a five-unit increase on the MFIS led to
a 1.7-times increase in the odds of having reported presenteeism.Table 3 – Correlations (95% CI) between clinical, PRO, and cogn
Absenteeism Presente
Clinical/cognitive measures
EDSS 0.09 (  0.04 - 0.21) 0.33 (0.21 -
Disease duration  0.02 (  0.10 - 0.09)  0.02 (  0.12
SDMT  0.08 (  0.18 -  0.002)  0.08 (  0.18
PRO measures
CES-D 0.05 (  0.06 - 0.17) 0.44 (0.32 -
MFIS 0.08 (  0.05 - 0.22) 0.54 (0.35 -
STAI-State 0.10 (  0.02 - 0.24) 0.33 (0.20 -
STAI-Trait 0.06 (  0.05 - 0.17) 0.39 (0.28 -
SF-36 component scales
SF-36: Physical
Functioning
 0.03 (  0.15 - 0.06)  0.43 (  0.55
SF-36: Role - Physical  0.13 (  0.30 -  0.003)  0.57 (  0.66
SF-36: Bodily Pain  0.08 (  0.17 - 0.04)  0.42 (  0.51
SF-36: General Health  0.12 (  0.24 - 0.06)  0.46 (  0.55
SF-36: Vitality  0.09 (  0.25 - 0.02)  0.48 (  0.57
SF-36: Social
Functioning
 0.03 (  0.13 - 0.06)  0.53 (  0.63
SF-36: Role - Emotional  0.07 (  0.21 - 0.03)  0.51 (  0.63
SF-36: Mental Health 0.02 (  0.11 - 0.13)  0.33 (  0.44
SF-36: Mental
Component Summary
 0.03 (  0.19 - 0.09)  0.48 (  0.58
SF-36: Physical
Component Summary
 0.12 (  0.24 -  0.02)  0.52 (  0.61
CES-D, Center for Epidemiologic Studies Depression Scale; CI, confiden
Fatigue Impact Scale; PRO, patient-reported outcome; SDMT, Symbol D
Health Survey; STAI, State-Trait Anxiety Inventory for Adults.
* Spearman correlation coefficient is reported.When a multivariate model for presenteeism was fit, statistically
significant associations with work productivity were observed for
fatigue, EDSS, and depression while controlling for the other
measures (Table 4). The R2 value for the full model was 0.35,
showing that the model explains a reasonable proportion of the
variance in presenteeism.
In terms of overall work productivity, similar but slightly
reduced correlations compared with those observed for presen-
teeism were found because this measure combines the absentee-
ism and presenteeism results (Table 3). These results showed that
reduced overall work productivity is associated with increasing
disability, depression, fatigue, anxiety, decreasing quality of life
for each of the SF-36 domains, and lower SDMT scores. No
statistically significant correlation with disease duration was
observed. The same factors that showed significant correlations
with overall work impairment also showed statistically signifi-
cant associations with the presence of overall work impairment
using logistic regression models (see Table 1 in Supplemental
Materials found at http://dx.doi.org/10.1016/j.jval.2012.07.010).
For the multivariate model, statistically significant associations
with overall work productivity were observed for fatigue and
EDSS while controlling for the other measures (Table 4). The R2
value for the full model was 0.26.
Predictors of Activity Impairment
Working and nonworking subjects contributed to our assessment
of activity impairment, and statistically significant correlations
between several clinical/PRO/cognitive measures and activity
impairment were observed (Table 3; also see Table 1 initive measures and work productivity measures.
eism Overall work
impairment
Activity impairment
0.43) 0.31 (0.19 - 0.41) 0.39 (0.29 - 0.47)
- 0.10)  0.02 (  0.12 - 0.09) 0.01 (  0.08 - 0.11)
- 0.03)  0.11 (  0.21 -  0.01)  0.12 (  0.23 -  0.01)
0.55) 0.37 (0.24 - 0.49) 0.50 (0.39 - 0.60)
0.63) 0.47 (0.32 - 0.58) 0.71 (0.63 - 0.76)
0.45) 0.31 (0.18 - 0.43) 0.39 (0.29 - 0.50)
0.50) 0.33 (0.20 - 0.45) 0.44 (0.33 - 0.54)
-  0.28)  0.35 (  0.48 -  0.22)  0.69 (  0.76 -  0.60)
-  0.42)  0.51 (  0.63 -  0.38)  0.71 (  0.77 -  0.62)
-  0.30)  0.36 (  0.46 -  0.24)  0.57 (  0.65 -  0.47)
-  0.35)  0.41 (  0.51 -  0.26)  0.52 (  0.60 -  0.40)
-  0.38)  0.42 (  0.53 -  0.29)  0.55 (  0.62 -  0.45)
-  0.38)  0.43 (  0.56 -  0.30)  0.68 (  0.76 -  0.57)
-  0.36)  0.44 (  0.57 -  0.30)  0.54 (  0.63 -  0.44)
-  0.21)  0.25 (  0.37 -  0.11)  0.40 (  0.49 -  0.29)
-  0.35)  0.39 (  0.52 -  0.23)  0.46 (  0.56 -  0.34)
-  0.41)  0.46 (  0.55 -  0.35)  0.72 (  0.78 -  0.64)
ce interval; EDSS, Expanded Disability Status Scale; MFIS, Modified
igit Modalities Test; SF-36, Medical Outcomes Study Short-Form 36
Table 4 – Multivariate model.
Absenteeism Presenteeism Overall work impairment Activity impairment
EDSS 0.38 (  1.12 - 2.39) 3.60 (1.7 - 6.6) 3.12 (0.84 - 6.08) 4.33 (2.57 - 6.19)
Disease duration  0.09 (  0.27 - 0.12)  0.11 (  0.35 - 0.15)  0.16 (  0.47 - 0.15)  0.07 (  0.28 - 0.15)
CES-D  0.06 (  0.76 - 0.33) 0.73 (0.23 - 1.24) 0.63 (  0.12 - 1.25) 0.68 (0.15 - 1.21)
MFIS 0.05 (  0.12 - 0.22) 0.41 (0.12 - 0.58) 0.48 (0.20 - 0.70) 0.88 (0.71 - 1.05)
STAI-Trait 0.03 (  0.20 - 0.32)  0.15 (  0.48 - 0.19)  0.15 (  0.52 - 0.25)  0.36 (  0.76 -  0.04)
SDMT  0.09 (  0.25 - 0.02) 0.06 (  0.08 - 0.20)  0.05 (  0.23 - 0.13) 0.12 (  0.02 - 0.31)
Note. Regression coefficients (95% CI) are presented so that each coefficient represents the change for a one-unit increase in each covariate.
Only STAI-Trait was included given the high known collinearity between STAI-State and STAI-Trait.
CES-D, Center for Epidemiologic Studies Depression Scale; CI, confidence interval; EDSS, Expanded Disability Status Scale; MFIS, Modified
Fatigue Impact Scale; SDMT, Symbol Digit Modalities Test; STAI, State-Trait Anxiety Inventory for Adults.
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2012.07.010). For all correlations presented in Table 3, the
correlations with activity impairment were stronger than with
work impairment, and the results showed that reduced activity is
associated with increasing disability, depression, fatigue, anxiety,
and decreasing quality of life for each of the SF-36 domains. A
statistically significant association with SDMTwas also observed,
but the correlation between SDMT and activity impairment was
lower than the correlations between activity impairment and the
other measures. The strongest correlations with activity impair-
ment were observed for fatigue (r ¼ 0.71; 95% CI 0.63–0.76),
Role-Physical (r ¼  0.71; 95% CI  0.77 to  0.62), and SF-36
PCS (r ¼  0.72; 95% CI  0.78 to  0.64). All the factors that
were significantly correlated with activity impairment were also
significantly associated with the presence of activity impairment
using logistic regressionmodels, with the exception of SDMT, which
was not significant (see Table 1 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2012.07.010). For the multivariate
model, statistically significant associations with activity impair-
ment were observed for depression, fatigue, EDSS, and STAI-Trait
(Table 4). The R2 value for the full model was 0.56, demonstrating
that the clinical/PRO/cognitive measures explain a high percentage
of the variance in the level of activity impairment.Discussion
We found that approximately 75% of the subjects with CIS/RRMS
who were surveyed were employed at the time of the study. This
number is higher than previously published employment rates in
MS [5]. The demographic characteristics of our study cohort may
explain this finding. Our patients had CIS/RRMS with mild
disability and had a mean age of 45 years. A progressive disease
course, greater disability, and increasing age have previously
been shown to be associated with unemployment in MS [4,7–9].
Fourteen percent of working subjects reported that they had
missed work in the last 7 day because of health problems, and
almost half of the working subjects reported that health pro-
blems affected their productivity while working. Subjects indi-
cated that they felt limited in the amount or kind of work they
did, accomplished less than they would like, and did not do their
work as carefully as usual. The mean work time missed because
of absenteeism was 3.6%, and the mean work time missed
because of presenteeism was 11.9%. Assuming that individuals
have a 40-hour workweek, this translates to 1.4 hours per week
lost because of absenteeism and 4.8 hours per week lost because
of presenteeism.
Compared with patients with other chronic diseases, CIS/
RRMS appears to have a more modest, but still measurable,
impact on work productivity. By using the WPAI:GH in patients
with rheumatoid arthritis, it was found that the mean work timemissed because of absenteeism was 8.7% and because of pre-
senteeism was 24.0% [17]. In studies that adapted the WPAI to a
specific disease or health state by referring to that disease rather
than health problems in general, absenteeism was reported to be
4.4% in irritable bowel syndrome [35], 5.0% in asthma [36], and
18.3% in Crohn’s disease [37]. Presenteeism was reported to be
32.4% in irritable bowel syndrome [35], 20.0% in asthma [36], and
40.5% in Crohn’s disease [37].
We observed statistically significant associations between
presenteeism and PRO measures of depression, fatigue, and anxi-
ety. Higher levels of depression, greater fatigue, and increased
anxiety were all associated with reduced productivity while work-
ing. In the multivariate model, fatigue showed the strongest effect
of all the factors included in the model based on the ratio of the
regression coefficient to the width of the CI. Fatigue is reported in
more than 80% of the patients with MS and is present early in the
course of the disease [38]. In a study of factors related to employ-
ment loss in MS, fatigue was the most commonly cited reason for
leaving work [7]. Although the underlying etiology of MS-related
fatigue is unclear, comprehensive treatment strategies have been
developed. A combination of nonpharmacologic and pharmacologic
therapies is recommended. They include lifestyle changes such as
increased exercise and smoking cessation and the use of medica-
tions including amantadine and modafinil [39]. It is possible that
the successful treatment of MS-related fatigue may improve pro-
ductivity while working and increase the likelihood of maintaining
employment for individuals with MS.
Depression was also significantly associated with presentee-
ism in both univariate and multivariate analyses. Depression
occurs in as many as half of all patients with MS at some point
during the course of the disease [40,41] and often goes untreated
[42,43]. Given the high prevalence of depression in MS and
the overlap between fatigue and the vegetative symptoms of
depression [9], the role of depression in the work life of indivi-
duals with MS should be carefully examined. Depression is
usually a treatable condition, and working patients with MS
might benefit from regular screenings and treatment for depres-
sive symptoms.
We found a significant association between presenteeism and
disability, but not disease duration. These results were confirmed
in the multivariate model, demonstrating that the impact of
disability remained even after controlling for fatigue. We are not
aware of any studies that specifically examined presenteeism
and disability in MS. There are numerous publications, however,
on employment status and disability. Kobelt et al. [44] estimated
production losses in MS at different levels of disease severity
across nine European countries. Employment rates ranged from
30% to 80% in patients with mild disability (EDSS scoreo 4.0),
10% to 75% in patients with moderate disability (EDSS score
4.0–6.5), and 0% to 10% in patients with severe disability (EDSS
score4 7.0). Glad et al. [12] studied the frequency of employment
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22.27 3.3 years. Benign disease was defined as an EDSS score of
r 3.0 at least 10 years after the onset of the disease. Significantly
more benign patients with MS (65%) than nonbenign patients
(17%) were employed, suggesting that disability and not duration
of disease was related to unemployment.
On the SF-36 physical and mental health scales, increased
presenteeism was significantly associated with decreased quality
of life. The strongest correlations were with Social Functioning,
Role-Physical, and Role-Emotional. The Social Functioning scale
measures the extent to which health interferes with normal
social activities such as visiting with friends or relatives. The
Role-Physical and Role-Emotional scales measure problems with
work or other daily activities as a result of physical health and
emotional problems. It seems that for working individuals with
MS, both physical and emotional problems are associated with
reduced productivity while working. In addition, the impact of
health problems on work performance is matched by its impact
on social and/or other regular activities. Psychological and
pharmacological interventions to address emotional problems
may be beneficial in improving both work productivity and social
functioning in MS.
Interestingly, we did not find a significant association between
presenteeism and cognitive functioning, and the SDMT was not
significantly associated with any of the WPAI:GH outcomes in the
multivariate models. The SDMT is a test of working memory and
speed of information processing that has been used as a screen-
ing tool for cognitive dysfunction in MS [45]. We expected that
reduced processing speed would impact work productivity. The
mean SDMT score was 56.7, which falls below published means
for healthy control subjects [45,46] but is higher than the
recommended cutoff score of 55 for cognitive dysfunction in
MS [45]. It is possible that this degree of impairment on the SDMT
is not sufficient to impact work productivity. More detailed
cognitive evaluations assessing numerous cognitive domains
including memory, spatial processing, verbal fluency, and execu-
tive functioning may be required. Although previous studies have
looked at cognitive function and employment status in MS [6,13],
it is not clear whether there are particular cognitive domains that
are associated with unemployment or reduced productivity at
work. It is also possible that cognitive impairment limits an
individual’s ability to accurately assess his or her own work
productivity.
Fifty-three percent of all subjects, those working for pay and
those not currently working for pay, reported that health pro-
blems affected their ability to do regular daily activities other
than working. Subjects indicated that health problems affected
their ability to do unpaid work such as housework, shopping,
childcare, exercising, and studying. The mean activity impair-
ment was 17.7%, suggesting that health problems have a sig-
nificant effect on unpaid work. Reduced activity was associated
with increased fatigue, depression, anxiety, and disability in both
univariate and multivariate models. Reduced activity was also
associated with decreased quality of life across all SF-36 domains.
Correlations between activity and PRO measures were stronger
than correlations between work productivity and PRO measures,
suggesting that fatigue and other mental health problems have
an even greater impact on regular daily activities than they have
on employment.
We did not observe statistically significant associations
between absenteeism and PRO measures. This may in part reflect
the fact that only a small proportion of subjects reported
absenteeism during the past 7 day. A similar pattern, however,
has been observed in other chronic diseases. Zhang et al. [17], for
example, found stronger correlations between presenteeism and
health status than between absenteeism and the same health
status measures in subjects with rheumatoid arthritis. When wefocused on predicting the presence of absenteeism by using the
logistic regression model, we found some predictors that were
significantly associated with absenteeism. The strength of these
associations, however, was smaller than the strength of the
associations with the presence of presenteeism. These findings
suggest that absenteeism and presenteeism may be measuring
separate dimensions of the impact of health problems on work
productivity.
There are several methodological limitations of this study.
First, there were no independent measures of missed work hours
or impairment while working. We relied instead on subject self-
report, which may not be accurate. Although it is possible to
verify work hours missed, it is much more difficult to identify
objective measures of impairment while working, which will vary
across occupations and workplaces [17]. Second, we did not
consider job type or occupational characteristics in the analysis.
It may be that work productivity is influenced by the type of work
done and that cognitively and physically demanding jobs are
associated with different rates of impairment while working [47].
Third, the WPAI:GH has not been validated against objective
measures of work productivity. It has also been shown to result
in higher estimates of presenteeism than other work productivity
instruments in patients with rheumatoid arthritis [48] and may
lead to overestimates of reduced work productivity in MS. Fourth,
this was a cross-sectional study that did not address health-
related changes in work status over time. It is possible that
subjects changed jobs, reduced hours, or modified work respon-
sibilities as a result of health-related issues and that work
productivity losses were underestimated because we did not
consider underemployment. Fifth, both subjects with CIS and
subjects with RRMS participated in the study. Subjects with CIS
and subjects with RRMS were combined on the basis of the strong
likelihood of subjects with CIS with abnormal MRI findings
converting to clinically definite MS [49] and the fact that
disease-modifying therapies are utilized and have been shown
to be of benefit in both RRMS and CIS [50]. When only subjects
with RRMS were included in the analyses, the results were largely
unchanged (data not shown). Sixth, because the CLIMB study is
not a patient registry but a volunteer cohort recruited from a
tertiary referral center, we cannot be sure that CLIMB participants
effectively represent the general populations of patients with MS
with either CIS or RRMS. Finally, this analysis was limited to
patients with CIS/RRMS, and the findings cannot be generalized
to the larger MS population. A future study should compare work
productivity in groups of patients with relapsing and
progressive MS.
In summary, CIS/RRMS was associated with reductions in
work productivity as well as unpaid work. Presenteeism, or
reduced productivity while working, was more common than
absenteeism or work time missed. Presenteeism was associated
with increased fatigue, depression, and anxiety and reduced
quality of life. Presenteeism was also associated with increased
severity of disease. Disease duration and cognitive function
were not associated with presenteeism. Future work should
investigate whether the early identification and treatment
of fatigue and mental health symptoms including depression
and anxiety might lead to increased productivity while working
and the ability to maintain paid employment for individuals
with MS.
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